Skip to main content

Table 4 Number of compounds mapping into individual cellular response categories of SOM

From: Identification of inhibitors of ovarian cancer stem-like cells by high-throughput screening

  F J M N P Q R S V
(a) 29 (4.2%) 44 (6.4%) 129 (18.7%) 102 (14.8%) 92 (13.3%) 83 (12.0%) 25 (3.6%) 140 (20.3%) 46 (6.7%)
(b) 5 (2.6%) 7 (3.6%) 70 (36.1%) 16 (8.2%) 25 (12.9%) 13 (6.7%) 5 (2.6%) 42 (21.6%) 11 (5.7%)
(c) 3 (1.9%) 5 (3.1%) 62 (38.5%) 16 (9.9%) 19 (11.8%) 9 (5.6%) 3 (1.9%) 35 (21.7%) 9 (5.6%)
(d) 2 (7.4%) 1 (3.7%) 6 (22.2%) 0 (0%) 5 (18.5%) 4 (14.8%) 1 (3.7%) 7 (25.9%) 1 (3.7%)
p-ab 0.3988 0.1653 <0.0001 0.0169 1.0000 0.0365 0.6537 0.6882 0.7412
p-ac 0.2469 0.1326 <0.0001 0.1283 0.6970 0.0163 0.3325 0.6663 0.7235
p-ad Numbers too small for statistical evaluation
  1. (a) all 793 evaluable compounds (b) 136 CSC inhibitory compounds; (c) 99 CSC and OVCAR-3 co-inhibitory compounds; (d) 32 CSC-specific inhibitory compounds. P-values: Fisher’s exact test for the significance of differences between proportions of compounds in a given cellular response category in 793 compound set (A) and compound subset B (p-AB), C (p-AC), or D (p-AD). [mitosis (M), membrane function (N), nucleic acid metabolism (S), metabolic stress and cell survival (Q), kinases/phosphatases and oxidative stress (P) and 4 unexplored regions (RFJV)].